# Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.

> **NCT04507061** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 243 (actual)

## Conditions studied

- Chronic Kidney Disease

## Interventions

- **DRUG:** runcaciguat
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04507061
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-01
- **Primary completion:** 2022-03-08
- **Final completion:** 2022-04-05
- **Target enrollment:** 243 (ACTUAL)
- **Last updated:** 2023-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04507061

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04507061, "Study on the Safety of the Drug Runcaciguat and How Well it Works When Given at the Highest Dose as Tolerated by Individual Patient Whose Kidneys Are Not Working Properly and Suffering at the Same Time From High Blood Sugar and/or High Blood Pressure and a Disease of the Heart and the Blood Vessels.". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT04507061. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*